1
|
E1 Clinical Safety for Drugs used in Long-Term Treatment/長期使用的藥物的臨床安全性
|
|
E1: The extent of Population Exposure to Assess Clinical Safety for Drugs Intended for Long-term Treatment of Non-life-threatening Conditions
|
E1:人群暴露程度:評估非危及生命性疾病長期治療藥物的臨床安全性
|
階段5
|
1994.10.27
|
有
|
2
|
E2A - E2F Pharmacovigilance/藥物警戒性
|
|
E2A: Clinical Safety Data Management: Definitions and Standards for Expedited Reporting
|
E2A: 臨床安全性數據管理:快速報告的定義和標準
|
階段5
|
1994.10.27
|
有
|
E2B(R3):Implementation Guide for Electronic Transmission of Individual Case Safety Reports (ICSRs) E2B(R3) Data Elements and Message Specification
|
E2B(R3):個例安全報告(ICSR)電子傳輸執行指導原則 E2B(R3)數據元素和信息規范元素 (中文版:征求意見稿)
|
階段5
|
2016.11.10
|
有
|
E2B(R3) QA document_v2_1
|
E2B(R3) 問答文件(中文版:征求意見稿)
|
階段5
|
2017.6.1
|
有
|
E2C(R2): Periodic Benefit-Risk Evaluation Report
|
E2C(R2): 定期獲益—風險評估報告
|
階段5
|
2012.12.17
|
有
|
E2C(R2) Implementation Working Group Questions & Answers
|
E2C(R2)實施工作組 問答部分
|
階段5
|
2014.3.31
|
有
|
E2D: Post-Approval Safety Data Management: Definitions and Standards for Expedited Reporting
|
E2D: 上市后安全性數據的管理:快速報告的定義和標準(中文版:征求意見稿)
|
階段5
|
2003.11.12
|
有
|
E2E: Pharmacovigilance Planning
|
E2E:藥物警戒計劃
|
階段5
|
2004.11.18
|
有
|
E2F:Example DSUR – Phase III Investigational Drug
|
E2F:研發期間安全性更新報告示例
|
|
2010.10.05
|
有
|
E2F: Development Safety Update Report
|
E2F:研發期間安全性更新報告
|
階段5
|
2010.8.17
|
有
|
3
|
E3 Clinical Study Reports/臨床研究報告
|
|
E3: Structure and Content of Clinical Study Reports
|
E3:臨床研究報告的結構與內容
|
階段5
|
1995.11.30
|
有
|
E3 Questions & Answers (R1) : Structure and Content of Clinical Study Reports
|
E3:臨床研究報告的結構和內容問與答(R1)
|
階段5
|
2012.7.6
|
有
|
4
|
E4 Dose-Response Studies/劑量反應研究
|
|
E4: Dose-Response Information to Support Drug Registration
|
E4:藥品注冊所需的量效關系信息
|
階段5
|
1994.3.10
|
有
|
5
|
E5 Ethnic Factors/種族因素
|
|
E5(R1): Ethnic Factors in the Acceptability of Foreign Clinical Data
|
E5(R1):接受國外臨床試驗數據的種族因素
|
階段5
|
1998.2.5
|
有
|
E5 Implementation Working Group Questions & Answers (R1)
|
E5:接受國外臨床試驗數據的種族因素問答(R1)
|
階段5
|
2006.6.2
|
有
|
6
|
E6 GCP/藥物臨床試驗管理規范
|
|
E6(R1): Guideline for Good Clinical Practice
|
E6(R1):藥物臨床試驗管理規范指導原則
|
階段5
|
1996.6.10
|
有
|
E6(R2):Integrated Addendum to Good Clinical Practice (GCP)
|
E6(R2):藥物臨床試驗管理規范綜合附錄
|
階段5
|
2016.11.9
|
|
7
|
E7 Clinical Trials in Geriatric Population/老人中開展的臨床試驗
|
|
E7: Studies in Support of Special Populations: Geriatrics
|
E7:特殊人群的研究:老年醫學
|
階段5
|
1993.6.24
|
有
|
E7 Questions & Answers
|
E7 特殊人群的研究:老年醫學問答
|
階段5
|
2010.7.6
|
有
|
8
|
E8 General Considerations for Clinical Trials/臨床試驗的一般性考慮
|
|
E8(R1): General Considerations for Clinical Trials
|
E8(R1):臨床試驗的一般考慮
|
階段5
|
2021.10.06
|
有
|
9
|
E9 Statistical Principles for Clinical Trials/臨床試驗的統計原則
|
|
E9: Statistical Principles for Clinical Trials
|
E9:臨床試驗的統計學原則
|
階段5
|
1998.2.5
|
有
|
E9(R1): Addendum on E stimands and Sensitivity Analysis in Clinical Trials
|
E9(R1):臨床試驗中的估計目標與敏感性分析(E9指導原則增補文件)
|
階段5
|
2019.11.20
|
有
|
10
|
E10 Choice of Control Group in Clinical Trials/試驗中對照組的選擇
|
|
E10: Choice of Control Group and Related Issues in Clinical Trials
|
E10:臨床試驗中對照組的選擇和相關問題
|
階段5
|
2000.7.20
|
有
|
11
|
E11 Clinical Trials in Pediatric Population/兒童人群臨床研究
|
|
E11(R1): Addendum: Clinical Investigation of Medicinal Products in the Pediatric Population
|
E11(R1):用于兒科人群的醫學產品的藥物臨床研究
|
階段5
|
2017.8.18
|
有
|
12
|
E12 Clinical Evaluation by Therapeutic Category/根據治療類別進行臨床評價
|
|
E12A: Principles for Clinical Evaluation of New Antihypertensive Drugs
|
E12A:抗高血壓新藥臨床評價原則
|
階段5
|
2000.3.2
|
有
|
13
|
E14 Clinical Evaluation of QT/QT臨床評價
|
|
E14: The Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs
|
E14:非抗心律失常藥物QT/QTc間期延長及致心律失常潛力的臨床評價
|
階段5
|
2005.5.12
|
有
|
E14 Implementation Working Group Questions & Answers (R3)
|
E14 實施工作組 問答部分(R3)
|
階段5
|
2015.12.10
|
有
|
E14/S7B: Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential Questions and Answers
|
E14/S7B: QT/QTc 間期延長及潛在致心律失常作用的臨床和非臨床評價問答
|
階段5
|
2022.02.21
|
有
|
14
|
E15 Definitions in Pharmacogenetics/Pharmacogenomics/藥物基因組學以及遺傳藥理學相關定義
|
|
E15: Definitions for Genomic Biomarkers, Pharmacogenomics, Pharmacogenetics, Genomic Data and Sample Coding Categories
|
E15:基因組生物標志物、藥物基因組學、遺傳藥理學、基因組數據和樣本編碼分類的定義
|
階段5
|
2007.11.1
|
有
|
15
|
E16 Qualification of Genomic Biomarkers/基因組生物標志物的合格條件
|
|
E16: Biomarkers Related to Drug or Biotechnology Product Development: Context, Structure and Format of Qualification Submissions
|
E16:藥物或生物技術產品開發相關的生物標志物:資格認定申請的背景資料、結構和格式
|
階段5
|
2010.8.20
|
有
|
16
|
E17 Multi-Regional Clinical Trials/多地區臨床試驗
|
|
E17: General principle on planning and Designing Multi-Regional Clinical Trials
|
E17:多區域臨床試驗計劃與設計的一般原則
|
階段5
|
2019.11.12
|
有
|
17
|
E18 Genomic Sampling/基因組取樣
|
|
E18: Genomic Sampling and Management of Genomic Data
|
E18:基因組采樣和基因組數據管理指導原則(中文翻譯公開征求意見稿)
|
階段5
|
2015.12.10
|
有
|
18
|
E19:A Selective Approach To Safety Data Collection In Specific Late-Stage Pre-approval Or Post-Approval Clinical Trials/在特定的上市前后期或上市后臨床試驗中選擇性收集安全性數據
|
|
E19:A Selective Approach To Safety Data Collection In Specific Late-Stage Pre-approval Or Post-Approval Clinical Trials
|
E19:在特定的上市前后期或上市后臨床試驗中選擇性收集安全性數據
|
階段5
|
2022.09.27
|
有
|